There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Find insight on Novo Nordisk, GSK and more in the latest Market Talks covering Health Care.

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

(RTTNews) - Danish healthcare company Novo Nordisk A/S (NVO ... Further, at the Annual General Meeting on March 27, the Board of Directors will propose a final dividend of 7.90 kroner for 2024 ...

Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Novo Nordisk forecasts 2025 sales growth will slow, citing increased competition for its obesity drug Wegovy and aligning ...

Novo Nordisk's GLP-1 receptor agonist semaglutide ... better than placebo at resolving MASH and improving liver fibrosis, meeting its primary efficacy objectives. Analysts have suggested that ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.